Affiliation:
1. From the University of North Carolina School of Medicine, Chapel Hill; Brody School of Medicine at Eastern Carolina University, Greenville, NC; Corvallis Clinic, Corvallis, OR; Clinical Research Consultants, Hoover, AL; Northwest Medical Specialties, Tacoma, WA; The Cleveland Clinic Foundation, Cleveland, OH; and Nuvelo Inc, San Carlos, CA.
Abstract
PurposeAlfimeprase is a recombinantly produced, genetically modified variant of the metalloproteinase, fibrolase. Alfimeprase proteolytically cleaves fibrin, independent of plasminogen activation to plasmin, and directly dissolves thrombi. Based on the direct fibrin degradation effect of alfimeprase, rapid activity in patients with occluded central venous access devices (CVADs) was hypothesized.Patients and MethodsWe performed a phase II, randomized, double-blind, active-control, multicenter, dose-ranging study to compare the safety and efficacy of one or two instillations of three intraluminal doses of alfimeprase (0.3, 1.0, and 3.0 mg) and alteplase 2.0 mg in re-establishing patency to occluded CVADs in 55 adult patients.ResultsAll three alfimeprase doses were more successful than alteplase during the first 15 and 30 minutes of treatment. The alfimeprase 3.0-mg dose resulted in 40%, 50%, and 60% patency restoration rates at 5, 15, and 30 minutes, respectively, compared with 0%, 0%, and 23% for alteplase. The difference at 15 minutes was highly significant (P = .0075). Alfimeprase 3.0 mg produced the highest patency rate at 120 minutes after the first (60%) and second (80%) doses. No major hemorrhagic or embolic events were reported.ConclusionA single 1- or 3-mg dose of alfimeprase has the potential to restore function to occluded CVADs rapidly and safely, and to facilitate on-time infusion of vital therapies.
Publisher
American Society of Clinical Oncology (ASCO)
Reference10 articles.
1. Welch GW, McKeel DW Jr, Silverstein B, et al: The role of catheter composition in the development of thrombophlebitis. Surg Gynecol Obstet 138:421,1974-424,
2. Restoring Patency of Occluded Central Venous Catheters
3. Ahmed NK, Tennant KD, Markland FS, et al: Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom. Haemostasis 20:147,1990-154,
4. Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basiliscus basiliscus: Cleavage site specificity towards the α-chain of fibrin
5. Barrett AJ: Alpha-2 macroglobulin, in Barrett AJ (ed): Methods in Enzymology . Philadelphia, PA, Academic Press, pp,1981 737-754
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献